J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McBride, B. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McBride, B. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

THERAPEUTIC REVIEW

The Emerging Role of Antiarrhythmic Compounds With Atrial Selectivity in the Management of Atrial Fibrillation

Brian F. McBride, PharmD

From the Chicago College of Osteopathic Medicine, Chicago College of Pharmacy, Midwestern University, and the Divisions of Cardiology and Pharmacy Practice, Department of Medicine, Rush University Medical Center, Chicago, Illinois.

Atrial fibrillation represents a significant source of cardiovascular morbidity and mortality in the United States. Despite a relatively high clinical failure rate, pharmacologic conversion to and maintenance of normal sinus rhythm with antagonists of the HERG potassium channel responsible for carrying the delayed rectifier current IKr represent a mainstay of therapy. Suppression of IKr leads to restoration of normal sinus rhythm but is also associated with ventricular proarrhythmia. Given the unique electrophysiologic targets expressed in human atrium, compounds that exhibit selectivity for these targets have the potential to restore sinus rhythm with a reduced risk of ventricular proarrhythmia. Targets with expression limited to human cardiac atria and compounds that interact with these targets are reviewed.

Key Words: Atrial fibrillation • antiarrhythmic agents • pharmacology • dofetilide • sotalol • amiodarone • potassium channels

Address for reprints: Brian F. McBride, PharmD, 555 31st Street, Suite 350, Downers Grove, IL 60515; e-mail: Bf.mcbride{at}comcast.net.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American College of Clinical Pharmacology